NCT00481520View on ClinicalTrials.gov

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-531

OTHER

placebo

Trial Locations (7)

10032

New York

30308

Atlanta

33009

Hallandale

33445

Delray Beach

33709

St. Petersburg

07740

Long Branch

05201

Bennington

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00481520 - Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter